Palantir Soars in Tech Talk, Shares Slip Premarket
Analysts at Wedbush Securities lifted their price target to $140 from $120, calling Palantir a generational tech name poised for a trillion-dollar market cap within three years after the company beat guidance and raised its outlook for fiscal 2025.
Josh Arnold of Timely Trader echoed the sentiment, calling the results another blowout and highlighting that free cash flow and operating profit guidance rose well ahead of revenue growth, implying significant runway for operating leverage going forward, though he warned valuation is catching up to fundamentals.
Morgan Stanley's Sanjit Singh agreed that Palantir is firing on nearly all cylinders, praising accelerating deal closures in both government and commercial markets amid broader macro uncertainty.
Singh kept an Equal-Weight rating but nudged his price target up to $98 from $90, citing 30%+ revenue growth and an 83% rule-of-40 score as evidence that Palantir has cemented its status as an AI software leader. Bank of America's Mariana Perez Mora maintained her Buy rating, noting that strong demand across segments drove the topline beat and continues to accelerate growth rates.
Why it matters: Palantir's Q1 performance reinforces its AI-driven growth story and operating leverage potential, but the premarket stock dip signals that investors remain wary of the premium valuation.
Investors will now focus on Q2 guidance and the pace of large deal closures in government and commercial pipelines when Palantir reports next quarter results.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J., August 01, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the "Freedom System") currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit View source version on Contacts Investor Contact: Louisa Smithinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22 minutes ago
- Business Wire
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ('KORU Medical' or the 'Company'), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the 'Freedom System') currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit
Hamilton Spectator
23 minutes ago
- Hamilton Spectator
Wall Street falls the most since May after employers slash hiring and tariffs roll out
The U.S. stock market had its worst day since May on Friday after the government reported a sharp slowdown in hiring and President Donald Trump imposed sweeping tariffs on imports from a number of U.S. trading partners. The S&P 500 fell 1.6%, its biggest decline since May 21 and its fourth straight loss. The index is also posted a 2.4% loss for the week, marking a sharp shift from last week's record-setting streak of gains. The Dow Jones Industrial Average fell 1.2%, while the Nasdaq composite fell 2.2%. Worries on Wall Street about a weakening economy were heavily reinforced by the latest report on job growth in the U.S. Employers added just 73,000 jobs in July. That is sharply lower than economists expected. The Labor Department also reported that revisions shaved a stunning 258,000 jobs off May and June payrolls. Markets also reacted to the latest tariff news . President Donald Trump announced tariff rates on dozens of countries and pushed back the scheduled effective date to Aug. 7, adding more uncertainty to the global trade picture.
